<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097069</url>
  </required_header>
  <id_info>
    <org_study_id>VITA01</org_study_id>
    <nct_id>NCT02097069</nct_id>
  </id_info>
  <brief_title>Inositol Stereoisomers to Treat Gestational Diabetes</brief_title>
  <official_title>Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to compare the effect of different inositol stereoisomers
      supplementation in lowering insulin resistance levels after 8 weeks of treatment in pregnant
      women with GDM and in preventing adverse obstetric outcomes.

      The study population includes 80 women with GDM, randomly allocated to subgroup A (folic acid
      400 mcg/day), subgroup B (myo-inositol 2000 mg twice a day), subgroup C (D-chiro-inositol 250
      mg twice a day), and subgroup D (Myo-inositol plus D-chiro-inositol 550mg/13,8 mg twice a
      day).

      Folic acid or inositol stereoisomers will be administered starting at the enrolling time
      (24-28 week gestation, after GDM diagnosis) till the delivery.

      The homeostasis model assessment of insulin resistance (HOMA-IR) and the sensitivity index
      (QUICKI) will be checked at the moment of the diagnostic oral glucose tolerance test (24-28
      weeks) and after 8 weeks of treatment. Obstetric outcomes, the rate of women needed insulin
      therapy and insulin dosage will be registered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance that begins or is
      first recognized during pregnancy (1). It is characterized by an increase of physiological
      insulin resistance and it is associated with an increased risk of perinatal and maternal
      morbidity (2,3).

      Inositol is a six-carbon polyol, normally present in a variety of foods, which has been
      classified as an insulin sensitizing agent. It exists as nine different isomers including
      myo-inositol (MI) and D-chiro-inositol (DCI) that are the most represented in human body.
      Myo-inositol and D-chiro-inositol glycans administration has been reported to exert
      beneficial effects at metabolic, hormonal and ovarian levels (4-5).

      Recently has been demonstrated that Myo-inositol supplementation improves insulin resistance
      in patients with GDM (6), whereas there aren't data about the use of D-chiro-inositol or
      Myo-inositol plus D-chiro-inositol in women affected by GDM.

      In this proposed study, the investigators aim to compare the effect of different inositol
      stereoisomers supplementation (Myo-inositol, D-chiro-inositol or Myo-inositol plus
      D-chiro-inositol ) in lowering insulin resistance levels after 8 weeks of treatment in
      pregnant women with GDM and in preventing adverse obstetric outcomes. All the available
      inositol formulations also contain folic acid (200 mcg).

      The study population includes 80 women with GDM, randomly allocated to subgroup A (folic acid
      400 mcg/day), subgroup B (myo-inositol 2000 mg twice a day), subgroup C (D-chiro-inositol 250
      mg twice a day), and subgroup D (Myo-inositol plus D-chiro-inositol 550mg/13,8 mg twice a
      day).

      Dietary control, folic acid or inositol stereoisomers will be administered starting at the
      enrolling time (24-28 week gestation, after GDM diagnosis) till the delivery.

      The homeostasis model assessment of insulin resistance (HOMA-IR) and the sensitivity index
      (QUICKI) will be checked at the moment of the diagnostic oral glucose tolerance test (24-28
      weeks) and after 8 weeks of treatment. Obstetric outcomes, the rate of women needed insulin
      therapy and insulin dosage will be registered.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance level evaluated by homeostasis model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>56 days- 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypertensive disorders</measure>
    <time_frame>56 days- 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macrosomia</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cesarean section</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal hypoglycemia</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>jaundice requiring phototherapy</measure>
    <time_frame>within the first 2 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>56 days- 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin therapy requirements</measure>
    <time_frame>56 days- 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subgroup A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>folic acid 400 mcg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myo-inositol 2000 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-chiro-inositol 250 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subgroup D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>Folic acid 400 mcg/day</description>
    <arm_group_label>Subgroup A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol</intervention_name>
    <description>myo-inositol 2000 mg twice a day</description>
    <arm_group_label>Subgroup B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-Chiro-inositol</intervention_name>
    <description>D-chiro inositol 250 mg twice a day</description>
    <arm_group_label>Subgroup C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol plus D-chiro inositol</intervention_name>
    <description>Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day</description>
    <arm_group_label>Subgroup D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational Diabetes diagnosed within 24-28 weeks gestation

          -  Caucasian pregnant women

        Exclusion Criteria:

          -  Pre-pregnancy diabetes

          -  Non-singleton pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital &quot;SS Annunziata&quot;</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ester Vitacolonna, Professor</last_name>
      <phone>+393398073446</phone>
      <email>e.vitacolonna@unich.it</email>
    </contact>
    <investigator>
      <last_name>Ester Vitacolonna, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998 Aug;21 Suppl 2:B161-7.</citation>
    <PMID>9704245</PMID>
  </reference>
  <reference>
    <citation>Casey BM, Lucas MJ, Mcintire DD, Leveno KJ. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol. 1997 Dec;90(6):869-73.</citation>
    <PMID>9397092</PMID>
  </reference>
  <reference>
    <citation>Jovanovic L, Pettitt DJ. Gestational diabetes mellitus. JAMA. 2001 Nov 28;286(20):2516-8. Review.</citation>
    <PMID>11722247</PMID>
  </reference>
  <reference>
    <citation>Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20.</citation>
    <PMID>10219066</PMID>
  </reference>
  <reference>
    <citation>Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct;95(10):1811-27. doi: 10.1016/j.biochi.2013.05.011. Epub 2013 Jun 10. Review.</citation>
    <PMID>23764390</PMID>
  </reference>
  <reference>
    <citation>Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug;28(8):972-5. doi: 10.1111/j.1464-5491.2011.03284.x.</citation>
    <PMID>21414183</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 23, 2014</last_update_submitted>
  <last_update_submitted_qc>March 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</investigator_affiliation>
    <investigator_full_name>Ester Vitacolonna</investigator_full_name>
    <investigator_title>Professor Ester Vitacolonna</investigator_title>
  </responsible_party>
  <keyword>Gestational diabetes mellitus</keyword>
  <keyword>Myo-inositol</keyword>
  <keyword>D-chiro-inositol</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

